门静脉高压症:经颈静脉肝内门体分流术的合理应用及其相关并发症的预防和处理*

doi:10.3969/j.issn.1672-5069.2023.01.002

Abstract

Lai Ruimin, Zhu Yuejiu. Portal hypertension: indication of transjugular intrahepatic portosystemic shunt and the prevention of related complications[J]. Journal of Practical Hepatology, 2023, 26(1): 4-7.

References

[1] Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. Mayo Clin Proc, 2019, 94(4): 714-726.
[2] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[3] Richter GM, Palmaz JC, Nöldge G, et al. The transjugular intrahepatic portosystemic stent-shunt. A new nonsurgical percutaneous method. Der Radiologe, 1989, 29(8): 406-411.
[4] Yin X, Gu L, Zhang M, et al. Covered TIPS procedure-related major complications: incidence, management and outcome from a single center. Front Med (Lausanne), 2022, 9: 834106.
[5] Garcia-Pagán JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol, 2013, 58(1): 45-50.
[6] García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med, 2010, 362(25): 2370-2379.
[7] Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology (Baltimore, Md), 2004, 40(4): 793-801.
[8] Palaniyappan N, Cox E, Bradley C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol, 2016, 65(6): 1131-1139.
[9] Pons M, Augustin S, Scheiner B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gstroenterol, 2021, 116(4): 723-732.
[10] 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南. 中华肝脏病杂志, 2019, 27(8): 582-593.
[11] Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet (London, England), 2003, 361(9361): 952-954.
[12] 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管,胃底静脉曲张破裂出血诊治专家共识(2019年版). 中国消化外科杂志, 2019, 18(12): 1087-1093.
[13] Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology (Baltimore, Md), 2017, 66(4): 1219-1231.
[14] Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut, 2018, 67(12): 2156-2168.
[15] Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md), 2016, 63(2): 581-589.
[16] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md), 2017, 65(1): 310-335.
[17] Hernández-Gea V, Procopet B, Giráldez Á, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study. Hepatology (Baltimore, Md), 2019, 69(1): 282-293.
[18] Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent Ascites. Gastroenterology, 2017, 152(1): 157-163.
[19] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2): 406-460.
[20] Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut, 2010, 59(7): 988-1000.
[21] Larrue H, Vinel JP, Bureau C. Management of severe and refractory ascites. Clin Liver Dis, 2021, 25(2): 431-440.
[22] Hewett LJ, Bradshaw ML, Gordon LL, et al. Diagnosis of isolated hepatic hydrothorax using peritoneal scintigraphy. Hepatology (Baltimore, Md), 2016, 64(4): 1364-1366.
[23] Banini BA, Alwatari Y, Stovall M, et al. Multidisciplinary management of hepatic hydrothorax in 2020: an evidence-based review and guidance. Hepatology (Baltimore, Md), 2020, 72(5): 1851-1863.
[24] Song T, Rössle M, He F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis, 2018, 50(4): 323-330.
[25] Guerrini GP, Pleguezuelo M, Maimone S, et al. Impact of tips preliver transplantation for the outcome posttransplantation. Am J Transplant, 2009, 9(1): 192-200.
[26] Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. Clin Gastroenterol Hepatol, 2018, 16(2): 162-177,e1.
[27] Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int, 2021, 15(3): 531-567.
[28] Saad WE, Darwish WM, Davies MG, et al. Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination. J Vasc Interv Radiol, 2010, 21(10): 1512-1520.
[29] Tripathi D, Macnicholas R, Kothari C, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther, 2014, 39(8): 864-872.
[30] Sun Y, Ma X, Feng L, Guan S, et al. Compensation by collateral circulation determines invasive therapeutic indications for patients with Budd-Chiari syndrome. Gut, 2012, 61(12): 1779-1780.
[31] Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis, 2012, 13(1): 33-39.
[32] Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis, 2011, 43(7): 503-514.
[33] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 临床肝胆病杂志, 2017, 33(9): 1627-1637.
[34] Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther, 2010, 31(3): 366-374.
[35] Violi F, Corazza GR, Caldwell SH, et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. Thromb Haemost, 2019, 119(3): 496-499.
[36] Fagiuoli S, Bruno R, Debernardi Venon W, et al. Consensus conference on TIPS management: Techniques, indications, contraindications. Dig Liver Dis, 2017, 49(2): 121-137.
[37] Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
[38] Chamarthy MR, Anderson ME, Pillai AK, et al. Thrombolysis and transjugular intrahepatic portosystemic shunt creation for acute and subacute portal vein thrombosis. Tech Vasc Interv Radiol, 2016, 19(1): 42-51.
[39] Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci, 2007, 52(11): 3290-3295.
[40] Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore, Md), 1999, 29(1): 62-67.

Portal hypertension: indication of transjugular intrahepatic portosystemic shunt and the prevention of related complications

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Xiaoquan, Chen Shiyao. Standardization treatment of patients with portal hypertension and gastroesophageal variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 1-3.
[2]	Chen Ye, Chen Xiaolan, Cao Liling, et al. Cardiac structural and functional changes in patients with hepatitis B cirrhosis after undergoing transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2023, 26(1): 79-82.
[3]	Xu Qing, Yang Jian, Zong Jinjuan. Imaging and histopathological features in patients with idiopathic non-cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2023, 26(1): 91-94.
[4]	Zhang Wei, Hou Wei, Liu Hui, et al. Recurrence three years after liver transplantation of patients with idiopathic portal hypertension: A case report and literature review [J]. Journal of Practical Hepatology, 2023, 26(1): 136-139.
[5]	Xu Chao, Li Lan, Luo Dong, et al.. Construction and application of risk prediction model for nosocomial death in cirrhotics with esophagogastric variceal bleeding after TIPS treatment [J]. Journal of Practical Hepatology, 2022, 25(6): 840-843.
[6]	Yang Jing, Cheng Yanli. Idiopathic non-cirrhotic portal hypertension: one case report and literature review [J]. Journal of Practical Hepatology, 2022, 25(5): 750-752.
[7]	He Wei, Zhang Xiaobin, Liu Yingdi, et al. Clinical features of patients with gastroesophageal varices under 30 years old [J]. Journal of Practical Hepatology, 2022, 25(4): 550-553.
[8]	Wang Chunyu, He Fuliang, Wang Yu. North American Practice - Based Recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension [J]. Journal of Practical Hepatology, 2022, 25(4): 0-S1,S2.
[9]	He Wei, Liu Xianguo, Wang Gang, et al. Radical surgery for treatment of patients with hepatic alveolus echinococcosis [J]. Journal of Practical Hepatology, 2022, 25(3): 435-438.
[10]	Hao Yuting, Lin Jie, Qin Jie. Clinical implication of serum aquaporin-8 and aquaporin-9 in patients with hepatitis B-induced liver cirrhosis receiving long-term entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(2): 243-246.
[11]	He Yibiao, Wang Zhipeng, Bai Lei. Short-term efficacy of three-dimensional visualization system and fiber choledochoscope in guiding hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2022, 25(2): 287-290.
[12]	He Fuliang, Ma Lin, Li Yuerong, et al. Non-cirrhotic portal hypertension:the highlight of its diagnosis [J]. Journal of Practical Hepatology, 2022, 25(1): 1-4.
[13]	Zhang Yu, Liu Fuquan. Precision technique and rational shunt in transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2022, 25(1): 5-8.
[14]	Chen Jing, Zhu Yueyong. Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging? [J]. Journal of Practical Hepatology, 2022, 25(1): 9-12.
[15]	Jiang Xiaoying, Yang Heng, Li Mingwu, et al. Prevention of drug-induced liver injury by orally diammonium glycyrrhetate in naïve patients with pulmonary tuberculosis [J]. Journal of Practical Hepatology, 2022, 25(1): 62-65.